1059-OR: TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1059-or ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von STEPHEN E. GITELMAN und 12 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Teplizumab (TPZ), an anti-CD3 monoclonal antibody, is approved in several countries to delay stage 3 type 1 diabetes (T1D) onset in individuals aged ≥8 years with stage 2. This is the first comprehensive study to characterize and follow individuals who received TPZ in the real world (RW).
Methods
In the chart review study, TEPLI-REAL (NCT06892002), all individuals with ≥1 day of TPZ treatment at 27 participating sites were followed until data abstraction.
Results
Among 110 individuals (US: n=101; Israel: n=9), 54% were female, 83% were White, 57% had a family history of T1D, 10% had Hashimoto’s, 4% had celiac disease. Median age was 13 years (range 8-62; 74% <18 years) at TPZ initiation. Median number of positive islet autoantibodies (IA) per individual was 3; 99% had ≥2 IA. Individuals were identified with dysglycemia first (41%), IA first (36%), or both at the same time (23%). Median HbA1c for these subgroups was 6.1% (n=41), 5.6% (n=32), and 6.0% (n=23), respectively, at or near screening. The median follow-up was 14.3 months. Most (94%) completed 14 days of TPZ. More than 70% remained in stage 2 T1D. Probability of remaining free of stage 3 per diagnostic pathway is shown in Figure.
Conclusion
This RW study shows high TPZ infusion completion in those ≥8 years and provides insights into treatment from different diagnostic pathways. Disclosure S.E. Gitelman: Advisory Panel; Current; Sanofi, SAB Biotherapeutics, Inc., Eli Lilly and Company, Genentech, Inc. Research Support; Current; Sanofi, SAB Biotherapeutics, Inc., GentiBio. Other - Member, DSMB; Current; Diamyd. Advisory Panel; Current; AnaptysBio, Inc. K. Simmons: None. T.E. Graham: Research Support; Current; Eli Lilly and Company, Novo Nordisk, Abbott Diagnostics, Tandem Diabetes Care, Inc., Sanofi, Novartis Pharmaceuticals Corporation. Advisory Panel; Current; Ascendis Pharma A/S. Research Support; Current; Ascendis Pharma A/S. Advisory Panel; Current; Sanofi. Research Support; Current; Sequel Med Tech. J. Felton: Advisory Panel; Ended; Sanofi. Other - Gave educational lectures.; Ended; Sanofi, Med Learning Group, LLC. A. Tirosh: Advisory Panel; Current; Medtronic. Research Support; Current; Medtronic. Speaker's Bureau; Ended; Sanofi. Advisory Panel; Ended; Sanofi. Research Support; Current; Sanofi. Speaker's Bureau; Ended; Novo Nordisk A/S, Eli Lilly and Company. Consultant; Current; DreaMed Diabetes, Ltd., Radella Pharma. M. Bonnemaire: Employee; Current; Sanofi. Stock/Shareholder; Current; Sanofi. C.B. Manzano Salgado: Employee; Current; Sanofi. Employee; Ended; IQVIA Inc. T.A. Dex: Stock/Shareholder; Current; Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd. F. Kleinjung: Employee; Current; Sanofi. J.M. Gwinnutt: Employee; Current; IQVIA Inc. F. Negreiro: Employee; Current; IQVIA Inc. J.H. Zaccai: Employee; Current; Sanofi. M. Tuffaha: None.
Zitieren
APA
GITELMAN, S. E., SIMMONS, K., GRAHAM, T. E., FELTON, J., TIROSH, A., BONNEMAIRE, M., SALGADO, C. B. M., DEX, T. A., KLEINJUNG, F., GWINNUTT, J. M., NEGREIRO, F., ZACCAI, J. H., & TUFFAHA, M. (2026). 1059-OR: TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1059-or
Vancouver
GITELMAN SE, SIMMONS K, GRAHAM TE, FELTON J, TIROSH A, BONNEMAIRE M, et al. 1059-OR: TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1059-or
BibTeX
@article{GITELMAN2026,
author = {GITELMAN, STEPHEN E. and SIMMONS, KIMBER and GRAHAM, TIMOTHY E. and FELTON, JAMIE and TIROSH, AMIR and BONNEMAIRE, MIREILLE and SALGADO, CYNTIA B. MANZANO and DEX, TERRY A. and KLEINJUNG, FRANK and GWINNUTT, JAMES M. and NEGREIRO, FILIPA and ZACCAI, JULIA H. and TUFFAHA, MARWA},
title = {1059-OR: TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1059-or}
}
EUVIMED